Urothelial Cancer: Progression After First-Line Therapy
Watch
Overview of Urothelial Cancer
Novel IL-2 Based Combinations for Bladder Cancer
Bladder Cancer
Managing Follicular Lymphoma as a Marathon, Not a Sprint
Adverse Events Associated With PI3K Inhibitors in FL
Choosing a PI3K Inhibitor in Relapsed Follicular Lymphoma
Exploring Options After Second-Line Relapse in FL
Early Relapse After Second-Line Chemoimmunotherapy in FL
Relapse After Second-Line Therapy in Follicular Lymphoma
Analyzing the Role of Checkpoint Inhibitors for the Treatment of Melanoma
Ryan J. Sullivan, MD, discusses the role of checkpoint inhibitors in the treatment landscape for patients with melanoma.
Reviewing the Latest Treatment Advancements in ALL
Elias Jabbour, MD, discusses the latest advancements in the treatment landscape for acute lymphocytic leukemia that are moving the paradigm away from chemotherapy.
Emerging Options and the Future of Follicular Lymphoma
Managing Toxicities of PI3K Inhibitors in FL
Second-Line Monotherapies in Follicular Lymphoma
Risk Prognostication in Follicular Lymphoma
Progression After R-CHOP: What Next?
Wide Range of Options in Frontline Follicular Lymphoma
Case Highlights: High-Risk Follicular Lymphoma
Case Review: Progression in Follicular Lymphoma
Highlighting the Latest Advancements in Bladder Cancer
Thomas W. Flaig, MD, discusses the most dramatic change in the treatment landscape for patients with advanced bladder cancer. Over the last several years, 5 checkpoint inhibitors have been approved in this space.
Assessing the Role of 21-Gene Assays in Breast Cancer
John H. Ward, MD, discusses the role of 21-gene assays in selecting patients with breast cancer for adjuvant chemotherapy treatment.
Analyzing Challenges in Treating Patients With Relapsed/Refractory Follicular Lymphoma
Carla Casulo, MD, discusses the challenges surrounding the treatment of patients with relapsed/refractory follicular lymphoma.
The Future of Polycythemia Vera Treatment
Ruxolitinib: Adverse Events & First-Line Plausibility
The Role of Ruxolitinib in Treating Polycythemia Vera
Rationale for Switching Polycythemia Therapy
Thrombosis, Myelofibrosis, and Acute Myeloid Leukemia
Polycythemia Vera: Treatment Goals & Risk Stratification
Diagnosing Polycythemia Vera
Case Overview: A 58-Year-Old Woman With Polycythemia Vera